| 2026-09-11 | Trial | New trial registered: A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegal | Trial register ClinicalTrials.gov |
| 2026-08-24 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2026-08-20 | Results | Results posted: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | Trial register ClinicalTrials.gov |
| 2026-07-22 | Label | FDA label revised: Sandostatin (NDA019667) | Regulator FDA drug label register |
| 2026-06-23 | Trial | New trial registered: A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokin | Trial register ClinicalTrials.gov |
| 2026-06-03 | Trial | New trial registered: A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly | Trial register ClinicalTrials.gov |
| 2026-06-01 | Results | Results posted: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Trial register ClinicalTrials.gov |
| 2026-05-13 | Recall | FDA recall, Class II: Teva Pharmaceuticals USA, Inc. Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administrat | Regulator FDA enforcement reports |
| 2026-05-13 | Trial | New trial registered: An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly | Trial register ClinicalTrials.gov |
| 2026-04-28 | Results | Results posted: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | Trial register ClinicalTrials.gov |
| 2026-04-08 | Trial | New trial registered: Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study | Trial register ClinicalTrials.gov |
| 2026-04-06 | Results | Results posted: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients | Trial register ClinicalTrials.gov |
| 2026-04-01 | Recall | FDA recall, Class II: Teva Pharmaceuticals USA, Inc. Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administrat | Regulator FDA enforcement reports |
| 2026-04-01 | Recall | FDA recall, Class II: Teva Pharmaceuticals USA, Inc. Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administrat | Regulator FDA enforcement reports |
| 2026-04-01 | Recall | FDA recall, Class II: Teva Pharmaceuticals USA, Inc. Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administrat | Regulator FDA enforcement reports |
| 2026-03-18 | Trial | New trial registered: Octreotide Microspheres for Preventing Pancreatic Fistula | Trial register ClinicalTrials.gov |
| 2026-03-10 | Trial | New trial registered: Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome | Trial register ClinicalTrials.gov |
| 2026-02-27 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2026-02-04 | Trial | New trial registered: Effect of Insulin Lowering on Lipogenesis | Trial register ClinicalTrials.gov |
| 2026-01-30 | Label | FDA label revised: Octreotide Acetate (ANDA216839) | Regulator FDA drug label register |
| 2026-01-21 | Label | FDA label revised: OCTREOTIDE ACETATE (ANDA216589) | Regulator FDA drug label register |
| 2026-01-21 | Results | Results posted: Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas | Trial register ClinicalTrials.gov |
| 2025-12-22 | Label | FDA label revised: Sandostatin LAR Depot (NDA021008) | Regulator FDA drug label register |
| 2025-12-04 | Trial | New trial registered: Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octre | Trial register ClinicalTrials.gov |
| 2025-11-28 | Trial | New trial registered: Hoffa's Fat Pad Impingement (HFPI) | Trial register ClinicalTrials.gov |
| 2025-11-20 | Results | Results posted: Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices | Trial register ClinicalTrials.gov |
| 2025-10-31 | Results | Results posted: Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | Trial register ClinicalTrials.gov |
| 2025-09-10 | Trial | New trial registered: Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendoc | Trial register ClinicalTrials.gov |
| 2025-08-29 | Trial | New trial registered: Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochr | Trial register ClinicalTrials.gov |
| 2025-08-05 | Trial | New trial registered: [18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease | Trial register ClinicalTrials.gov |
| 2025-08-03 | Trial | New trial registered: 18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms | Trial register ClinicalTrials.gov |
| 2025-07-24 | Label | FDA label revised: Mycapssa (NDA208232) | Regulator FDA drug label register |
| 2025-07-24 | Label | FDA label revised: Mycapssa (NDA208232) | Regulator FDA drug label register |
| 2025-07-10 | Trial | New trial registered: A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs | Trial register ClinicalTrials.gov |
| 2025-07-09 | Trial | New trial registered: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Trial register ClinicalTrials.gov |
| 2025-06-25 | Label | FDA label revised: OCTREOTIDE ACETATE (ANDA217860) | Regulator FDA drug label register |
| 2025-05-15 | Trial | New trial registered: Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial) | Trial register ClinicalTrials.gov |
| 2025-05-09 | Results | Results posted: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | Trial register ClinicalTrials.gov |
| 2025-04-09 | Trial | New trial registered: A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs | Trial register ClinicalTrials.gov |
| 2025-03-18 | Trial | New trial registered: Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema | Trial register ClinicalTrials.gov |
| 2025-03-17 | Results | Results posted: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) | Trial register ClinicalTrials.gov |
| 2025-03-17 | Trial | New trial registered: Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors | Trial register ClinicalTrials.gov |
| 2025-03-10 | Trial | New trial registered: Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas | Trial register ClinicalTrials.gov |
| 2025-03-04 | Trial | New trial registered: Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients | Trial register ClinicalTrials.gov |
| 2025-02-21 | Label | FDA label revised: BYNFEZIA Pen (NDA213224) | Regulator FDA drug label register |
| 2025-01-20 | Trial | New trial registered: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Trial register ClinicalTrials.gov |
| 2025-01-16 | Label | FDA label revised: Octreotide Acetate (ANDA075957) | Regulator FDA drug label register |
| 2024-12-31 | Trial | New trial registered: Polydeoxyribonucleotide for Elbow Lateral Epicondylitis | Trial register ClinicalTrials.gov |
| 2024-12-03 | Label | FDA label revised: OCTREOTIDE ACETATE (ANDA203765) | Regulator FDA drug label register |
| 2024-10-10 | Results | Results posted: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET | Trial register ClinicalTrials.gov |
| 2024-09-19 | Trial | New trial registered: Graded Insulin Suppression Test P&F | Trial register ClinicalTrials.gov |
| 2024-08-16 | Trial | New trial registered: Human Models of Selective Insulin Resistance: Pancreatic Clamp | Trial register ClinicalTrials.gov |
| 2024-07-30 | Label | FDA label revised: Octreotide Acetate (ANDA210317) | Regulator FDA drug label register |
| 2024-07-29 | Label | FDA label revised: Octreotide Acetate (ANDA216839) | Regulator FDA drug label register |
| 2024-07-25 | Label | FDA label revised: Octreotide Acetate (ANDA216807) | Regulator FDA drug label register |
| 2024-07-24 | Results | Results posted: Effects of Sandostatin LAR® in Acromegaly | Trial register ClinicalTrials.gov |
| 2024-07-17 | Trial | New trial registered: A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tu | Trial register ClinicalTrials.gov |
| 2024-07-15 | Label | FDA label revised: Octreotide Acetate (ANDA079198) | Regulator FDA drug label register |
| 2024-05-23 | Label | FDA label revised: Octreotide (ANDA077457) | Regulator FDA drug label register |
| 2024-05-22 | Trial | New trial registered: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positi | Trial register ClinicalTrials.gov |
| 2024-05-07 | Label | FDA label revised: Octreotide (ANDA077457) | Regulator FDA drug label register |
| 2024-03-14 | Trial | New trial registered: 177Lu-DOTATATE for Recurrent Meningioma | Trial register ClinicalTrials.gov |
| 2024-03-14 | Trial | New trial registered: Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours | Trial register ClinicalTrials.gov |
| 2024-03-08 | Trial | New trial registered: A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors | Trial register ClinicalTrials.gov |
| 2024-03-05 | Results | Results posted: A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors | Trial register ClinicalTrials.gov |
| 2024-03-01 | Label | FDA label revised: Octreotide Acetate (ANDA076313) | Regulator FDA drug label register |
| 2024-02-12 | Trial | New trial registered: Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers | Trial register ClinicalTrials.gov |
| 2024-02-02 | Trial | New trial registered: Direct Versus Indirect Effect of Amino Acids on Hepatokines | Trial register ClinicalTrials.gov |
| 2024-01-05 | Trial | New trial registered: Outcome of ADPKD With Octreotide LAR | Trial register ClinicalTrials.gov |
| 2023-11-13 | Trial | New trial registered: Dexamethasone/Pancreatic Clamp P&F | Trial register ClinicalTrials.gov |
| 2023-10-17 | Trial | New trial registered: Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements. | Trial register ClinicalTrials.gov |
| 2023-10-12 | Trial | New trial registered: Real-world Study on Adjuvant Octreotide Therapy in pNETs | Trial register ClinicalTrials.gov |
| 2023-10-02 | Trial | New trial registered: Role of Octreotide in Non Variceal Bleeding | Trial register ClinicalTrials.gov |
| 2023-09-13 | Trial | New trial registered: "Receptor Radionuclide Therapy With 177Lu-DOTATOC | Trial register ClinicalTrials.gov |
| 2023-06-01 | Trial | New trial registered: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | Trial register ClinicalTrials.gov |
| 2023-05-30 | Trial | New trial registered: Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, So | Trial register ClinicalTrials.gov |
| 2023-04-26 | Trial | New trial registered: Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 | Trial register ClinicalTrials.gov |
| 2023-03-09 | Trial | New trial registered: A Single-dose Study of Octreotide Injection in Healthy Adult Subjects | Trial register ClinicalTrials.gov |
| 2023-03-06 | Trial | New trial registered: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. | Trial register ClinicalTrials.gov |
| 2023-03-01 | Trial | New trial registered: Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression | Trial register ClinicalTrials.gov |
| 2023-02-13 | Trial | New trial registered: Pancreatic Clamp in NAFLD | Trial register ClinicalTrials.gov |
| 2023-02-09 | Results | Results posted: Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | Trial register ClinicalTrials.gov |
| 2023-01-13 | Trial | New trial registered: Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial | Trial register ClinicalTrials.gov |
| 2023-01-12 | Trial | New trial registered: The Effect of Octreotide on Wound Drainage After Mastectomy | Trial register ClinicalTrials.gov |
| 2023-01-05 | Trial | New trial registered: Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients | Trial register ClinicalTrials.gov |
| 2023-01-04 | Results | Results posted: Acromegaly Combination Treatment Study | Trial register ClinicalTrials.gov |
| 2022-11-29 | Results | Results posted: Palliative Management of Inoperable Malignant Bowel Obstruction | Trial register ClinicalTrials.gov |
| 2022-11-16 | Recall | FDA recall, Class I: Viatris Inc. Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe. | Regulator FDA enforcement reports |
| 2022-07-28 | Trial | New trial registered: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Trial register ClinicalTrials.gov |
| 2022-07-15 | Trial | New trial registered: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | Trial register ClinicalTrials.gov |
| 2022-05-26 | Results | Results posted: Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy | Trial register ClinicalTrials.gov |
| 2022-05-13 | Results | Results posted: Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults | Trial register ClinicalTrials.gov |
| 2022-05-04 | Trial | New trial registered: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gast | Trial register ClinicalTrials.gov |
| 2022-04-27 | Trial | New trial registered: Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | Trial register ClinicalTrials.gov |
| 2022-04-27 | Trial | New trial registered: Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) | Trial register ClinicalTrials.gov |
| 2022-04-22 | Results | Results posted: Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly | Trial register ClinicalTrials.gov |
| 2022-04-22 | Trial | New trial registered: Effect of Octreotide on Saliva | Trial register ClinicalTrials.gov |
| 2022-04-21 | Trial | New trial registered: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. | Trial register ClinicalTrials.gov |
| 2022-03-16 | Trial | New trial registered: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD | Trial register ClinicalTrials.gov |
| 2022-01-20 | Trial | New trial registered: Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled S | Trial register ClinicalTrials.gov |